Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Acelyrin's Izokibep?
Izokibep is a fusion protein commercialized by Acelyrin, with a leading Phase III program in Psoriatic Arthritis. According to Globaldata,...
Izokibep by Acelyrin for Psoriatic Arthritis: Likelihood of Approval
Izokibep is under clinical development by Acelyrin and currently in Phase III for Psoriatic Arthritis. According to GlobalData, Phase III...
Risk adjusted net present value: What is the current valuation of Acelyrin's Izokibep?
Izokibep is a fusion protein commercialized by Acelyrin, with a leading Phase III program in Psoriatic Arthritis. According to Globaldata,...
Izokibep by Acelyrin for Hidradenitis Suppurativa: Likelihood of Approval
Izokibep is under clinical development by Acelyrin and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III...